Prognostic Factors in Pancreatic Cancer

  • Georgios Michael Oikonomopoulos Second Oncology Department, St. Savvas Anticancer Hospital. Athens, Greece
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School. Athens, Greece
  • Muhammad Wasif Saif Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA
Keywords: Antigens, CD3, CD4, CD8, Equilibrative Nucleoside Transporter 1, Neoplastic Cells, Circulating, Osteonectin, Pancreatic Neoplasms, Predictive Value of Tests, Prognosis, SPARC protein, human

Abstract

Pancreatic cancer is a frequent and lethal disease ranking fourth as a cause of cancer-related death in Western countries. There are patients, though, who respond well to chemotherapy and have a prolonged survival. There is an effort towards identification of specific characteristics of these tumor cells in order to identify those patients who will benefit from chemotherapy and use them as prognostic or predictive factors. This review is an update on the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in this field for pancreatic cancer, as they were reported in Abstracts #4006, #4016, #4046, and #4060 and a discussion is presented about their application in clinical praxis.

Image: St. Savvas Hospital. Athens, Greece.

Downloads

Download data is not yet available.

References

Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003;22:7524–7536

Farell J. J., Elsaleh H., Garcia M., et.al Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology 2009;136:187–195

Jian-Chun Xiao, Tai-Ping Zhang et al. hENT1 predicts the Asian patient response to Gemcitabine-based chemotherapy in Pancreatic Cancer. Hepatogastroenterology 2013;60(122):Ahead of print

Mahadevan D, Von Hoff DD. Tumor–stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186–97

Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101:887–907

Manuel Hidalgo and Daniel D. Von Hoff. Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas. Clin Cancer Res 2012;18:4249-4256

Negin B. P., Meropol N. J., Alpaugh R. K.,et. al Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2010 Vol 28, No 15_suppl 2010: 4127

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28:e26–3

Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12:5423–34)

Neoptolemos J. P., Greenhalf W., Ghaneh P, et al. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 31, 2013 (suppl; abstr 4006)

Sinn M., Sinn VB., Striefer JK., et.al SPARC in pancreatic cancer: Results from the CONKO-001 study. J Clin Oncol 31, 2013 (suppl; abstr 4016)

Huhuet F., Bidard FC., Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma. The ancillary study Circe-07 of the LAP-07 trial J Clin Oncol 31,2013 (suppl abstr 4046)

Turcotte S., McNikoll Y., Soucy G., et al. Prognostic value of an immune score combining intra- and peritumoral T-cell subset density in patients with pancreatic adenocarcinoma J Clin. Oncol 31, 2013 (suppl; abstr 4060)

Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319–25

Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, et al. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 2010;3:57–72

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548–54

Toshio K, Takao I, Atshushi S et al. Detection of circulating tumor cells in patients with pancreatic cancer: A preliminary result J. Hepatobilliary Pancr Surg. 2008;15:189-195

St. Savvas Hospital. Athens, Greece
Published
2013-07-10
How to Cite
Oikonomopoulos, G., Syrigos, K., & Saif, M. (2013). Prognostic Factors in Pancreatic Cancer. JOP. Journal of the Pancreas, 14(4), 322-324. https://doi.org/10.6092/1590-8577/1644
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Most read articles by the same author(s)

1 2 > >>